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ABSTRACT
Robust research over the past 30 years has led recently to the first approval of genetically enhanced T lympho-
cytes expressing chimeric antigen receptors (CAR T-cells) as a tool to fight cancer. The backbone of the afore-
mentioned therapy is to equip patients’ T lymphocytes in a genetically modified receptor that can recognise the 
antigen present on the surface of a cancer cell with the accuracy of a specific antibody, and to ignite a cytotoxic 
reaction against it with the function of the T-lymphocyte receptor. Ground-breaking results achieved in patients 
with haematological malignancies led to multiple clinical trials of CAR T-cell-based therapy in solid tumours. Re-
gardless of the initial hurdles, recent reports suggest that continuous evolution and further improvements of CAR 
T-cell therapy for solid tumours is as successful as that observed in haematology. Despite the fact that enormous 
efforts are still to be made, implementation of CAR T-cells into the clinical oncologist’s daily routine practice was 
never as plausible as it is today. 
Key words: personalised medicine, genetic modifications, CAR T-cell therapy, solid tumours, haematological 
malignancies
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Introduction
Over the years, different areas of cancer biology 
have been explored to find a cure for cancer, the disease 
with complex, advanced mechanisms that can easily 
outsmart the best research teams despite their enormous 
efforts. Only a few studies every year have succeeded to 
provide a regimen significantly improving the survival of 
cancer patients. There was an urgency to search other 
versatile and intelligent approaches for a more effective 
fight against cancer. The very best field to exploit ap-
peared to be immunotherapy and enhancing the func-
tion of patients’ own immunological system by equipping 
its immunocompetent cells with additional functions to 
independently combat malignant cells. 
By altering immunologic response against cancer 
cells researchers seemed to significantly improve the 
outcomes in comparison with standard systemic chemo-
therapy. Immunologic response can be guided in various 
ways, and the basic studies in that area were rewarded 
with the Nobel Prize this year, providing a backbone for 
the discovery of checkpoint inhibitors, e.g. ipilimumab, 
pembrolizumab, nivolumab, atezolizumab, durvalumab, 
and avelumab, which have already been successfully im-
plemented into clinical practice. The other approach is 
directed at increasing the number of tumour infiltrating 
lymphocytes (TILs), the concentration of which in solid 
tumours and surrounding stroma is known as a good 
prognostic factor [1]. The last and the most advanced 
area of cancer immunotherapy is genetic engineering 
of patients’ immunocompetent cells to produce clones 
that can act more effectively and accurately, and this 
area will be discussed in this publication.
The idea of CAR T-cell therapy
Chimeric antigen receptor T-cells (CAR T-cells) are 
T-lymphocytes genetically modified to express on their 
surface powerful receptors with enhanced ability to ef-
fectively attack cancer cells. Normal T-lymphocytes are 
unable to fight cancer effectively because they require 
Oncology in Clinical Practice
2019, Vol. 15, No. 4, 202–207
DOI: 10.5603/OCP.2019.0016
Copyright © 2019 Via Medica
ISSN 2450–1654
203
Ewa Wrona, Piotr Potemski, A novel immunotherapy — the history of CAR T-cell therapy
major histocompatibility complex (MHC) class I/II anti-
gen recognition to ignite their reaction, and cancer cells 
deliberately inhibit MHC expression on their surface to 
be “invisible” to immunocompetent cells. The main con-
cept is to equip patient’s T-lymphocytes with additional 
functionalities to improve recognition, trafficking, and 
action against cancer cells. Genetic alterations result 
in creating T-cell receptor (TCR) with an extracellular 
domain substituted by a fragment of a specific antibody 
against cancer antigen (scFv). In this way we can com-
bine both of its functions in one chimeric protein: the 
ability to trigger T-lymphocyte cytotoxic reaction and 
to recognise with the accuracy of an antibody a chosen 
antigen on the surface of a malignant cell without the 
need for MHC class I/II recognition. Additionally, it is 
known that adding further co-stimulators to CAR pro-
tein can prolong T-cell viability and enhance cytotoxic 
reaction, among other functions [1, 2]. 
Surprisingly, the very idea of genetically modified 
receptors on the surface of immunocompetent cells is 
not recent. The first report on chimeric combination 
of receptors and antibodies was published in 1989 by 
Weizmann Institute in Israel [3]. Since then a great 
amount of effort has been devoted into this area of 
research, leading to therapeutic success in 2012 when 
seven-year-old Emily Whitehead was cured from 
relapsed/refractory B-cell acute lymphoblastic leukae-
mia (R/R B-ALL) with infusion of anti-CD19 CAR 
T-cells. CD19 is an example of the ideal antigen for CAR 
T-cell recognition because it is expressed exceptionally 
on every B lymphocyte as well as on blast cells that origi-
nate from the B-cell line. Her case was a breakthrough 
not only because she was the first patient with R/R 
B-ALL, who achieved complete remission after a single 
course of treatment, but also because she was the very 
first child enrolled into a clinical study with tisagenle-
cleucel (Kymriah, Novartis) CAR T-cell therapy. Her 
case was broadcasted worldwide as an example of this 
miraculous drug, with headlines playfully reporting the 
girl cured from cancer by HIV (actually, the HIV virus 
was used only as a vector in the transduction process) 
[4]. At the time of writing this manuscript she is still in 
complete remission advocating in favour of implement-
ing wider access to CAR T-cell therapy. 
Manufacturing process 
To start to produce CAR T-cells eligible for adminis-
tration to the patient, a labour-intensive process that 
requires the cooperation of both clinical and laboratory 
staff must be undertaken with many carefully performed 
steps. Firstly, viable T-cells need to be collected from 
peripheral blood or through leukapheresis. Next, 
Th17 lymphocytes are filtered and their gross number 
increased by enforcing T-cell multiplication ex vivo. Then 
a previously prepared viral vector containing genetic in-
formation about what the future chimera of the antibody 
and receptor should look like and what kind of antigen 
it should recognise transports the information into the 
infected T-cell. For the transfection process several 
viruses (especially lentivirus or retrovirus) or plasmids 
are used. Of course, the viral genome must be altered 
to silence its own virulence after transfection [5]. As for 
vector production improvement, a highly accurate and 
efficient CRISPR/cas9 endonuclease system, as well 
as a TALEN gene-editing tool, finds their implication, 
making the production process far more precise and 
increasing the throughput [6, 7]. The basis of the trans-
fection process is to incorporate the message into the 
T-lymphocyte genome to enforce expression of numer-
ous functional CARs across its membrane. 
Solution of transfected T-cells with high expres-
sion of CARs on their surface is further expanded 
in a cell culture, washed, suspended in a mixture of 
DMSO/dextran 40/HSA/dextrose/Plasma-Lyte A, and 
cryopreserved. Sterility tests are conducted before 
shipping to the facility where it will be administered to 
the patient [8, 9]. 
Clinical applications in haematological 
malignancies
Administration requires premedication with parac-
etamol and H1-antihistamine. Regarding dosing, there 
are different ranges of total viable CAR T-cells, which 
vary between children and adults with numbers between 
0.2 × 106 and 6.0 × 108 per kilogram body weight 
CAR-positive T-cells for Kymriah, and 2 × 106 CAR 
T-cells per kilogram body weight for Yescarta (trade 
name for axicabtagene ciloleucel, Gilead, approved for 
treatment of R/R large B-cell lymphoma). Calculated 
total number of cells is later infused over three to four 
doses administered with short breaks one after another 
[8, 9]. Prior to the infusion the patient must undergo 
lymphodepleting chemotherapy (fludarabine and cyclo-
phosphamide or equivalent) provided that his/her white 
blood cell (WBC) count is higher than 1 × 109/L. CAR 
T-cell infusion must be administered between the second 
and 14th day after completion of the lymphodepleting 
chemotherapy [9]. 
There are many limitations of this treatment. Apart 
from limited availability of the technology and economic 
factors, patient specific eligibility criteria must be ful-
filled. At the moment of publication FDA registration 
applies to patients with R/R B-cell ALL and adults with 
R/R B-cell lymphomas (Table 1). However, efforts are 
being made to expand those indications for follicular 
lymphoma (FL) and chronic lymphoblastic leukaemia 
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(CLL). Last but not least, the patient must be able to 
have his/her lymphocytes harvested, which excludes 
cases with deep lymphopaenia (less than 300/μL). Viral 
infections, e.g. HIV, HCV, or HBV, excludes patients 
from enrolment, as well as active autoimmune disease 
requiring immunosuppressive therapy. Candidates 
must also be fit for conditioning chemotherapy with 
cyclophosphamide and fludarabine or equivalent prior 
to CAR T-cell infusion with the baseline ECOG per-
formance status of 0–1 [8, 9]. 
Anticipated adverse events
Unluckily, serious adverse events grade 3 or higher 
occur in the vast majority of patients treated with Kym-
riah or Yescarta. Based on the ELIANA and JULIET 
trials for Kymriah and ZUMA-1 for Yescarta we can 
assess their incidence as 83% for B-lymphocyte aplasia, 
49% for cytokine release syndrome (CRS), 37% for 
febrile neutropaenia, 22% for hypotension, 18% for hy-
poxia, 15% for pyrexia, 15% for acute kidney injury, 10% 
for encephalopathy, and 10% for pulmonary oedema, 
among others [9]. 
CRS and neuro toxicities are most life-threatening 
side effects associated with CAR T-cells infusion. CRS 
arises from activation of CAR T-cells and death of tar-
geted cells after antigen recognition and TNFa, IL-6 and 
IFNg release among others, triggering an avalanche of 
reactions, which is unlikely to limit itself. The syndrome 
manifests with fever, hypotension, hypoxia, and tachy-
cardia and can be associated with multiple organ failure 
and coagulopathy. Severity of CRS is known to correlate 
with tumour burden. It was observed that fractionation 
of the infusion volume into 3–4 smaller portions may 
decrease the risk of CRS. It usually occurs 2–3 days 
after infusion and lasts for approximately eight days if 
treated [10]. 
The majority of neurologic toxicities, e.g. delirium, 
aphasia, seizures, and encephalopathy, are thought to be 
reversible; however, the mechanism of central nervous 
system involvement is not fully understood. Neuro toxici-
ties grade 3 or higher occurred in 31% of patients with 
median time to onset of four days and median duration 
of 17 days. There were four deaths related to Yescarta 
and one to Kymriah reported in the aforementioned 
studies, all of them due to CRS [8, 9]. 
One of the natural side effects of CAR T-cell anti- 
-CD19 therapy is B-lymphocyte aplasia. It was proven 
that some of B-lymphocytes can lack CD19 expression 
and flee this way from CAR T-cell activity sustaining 
baseline immunocompetence, although the majority of 
patients require replacement therapy with intravenous 
immunoglobulin and prophylactic antibiotics [1, 5]. 
Aplasia is thought to be a long-lasting side effect that 
is present at six months after the treatment in 83% of 
patients (95% CI 69–91%) [11]. 
Management of side effects
Management of side effects requires standard 
symptomatic treatment, although for CRS and 
neuro-toxicities grade 2 or higher, administration of 
tocilizumab alone or with corticosteroids is recom-
mended as well [8, 9]. Tocilizumab is an immuno-
suppressive drug inhibiting specifically IL-6, widely 
available in Poland in the therapy of rheumatoid 
arthritis (RoActemra, Roche). The US Food and Drug 
Administration (FDA) approved tocilizumab for treat-
ment of CRS triggered by CAR T-cell therapy. It is 
suggested the administration of 8 mg/kg intravenously 
over one hour repeating every eight hours if needed. 
A maximum of three doses in a 24-hour period can 
be administered with a total of four doses [8, 9]. If 
there is no improvement within 24 hours after starting 
tocilizumab, administration of corticosteroids as well, 
preferably methylprednisolone 1 mg/kg intravenously 
twice a day or dexamethasone 10 mg every six hours, 
is recvommended [8, 9]. 
Table 1. FDA-approved indications for both tisagenlecleucel and axicabtagene ciloleucel
Generic name Brand 
name
FDA 
approval 
date
Indications
Tisagenlecleucel Kymriah, 
Novartis
August 30, 
2017
For patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia 
(ALL) that is refractory or in second or later relapse [9] 
May 1, 
2018
For adult patients with R/R large B-cell lymphoma after two or more lines of systemic 
therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-
grade B-cell lymphoma and DLBCL arising from follicular lymphoma [9] 
Axicabtagene 
ciloleucel
Yescarta, 
Gilead
October 
18, 2017
For adult patients with relapsed or refractory large B-cell lymphoma after two or more 
lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise 
specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and 
DLBCL arising from follicular lymphoma [8] 
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Clinical trials 
Based on clinical trial data that led to Yescarta and 
Kymriah FDA approval for adults with R/R B-cell lym-
phoma (ZUMA-1 and JULIET study), we acknowledge 
the progression-free survival (PFS) rate at 15 months to 
be 41% (95% CI 31–50), median duration of response to 
be 11.1 months (95% CI 3.9 to could not be estimated), 
the median PFS to be 5.8 months (95% CI 3.3 to could 
not be estimated), and OS rates of 52% at 18 months 
with median overall survival (OS) not reached (95% CI 
12.0 months to could not be estimated) [12]. 
For Kymriah, in the ELIANA study of 75 patients 
not older than 21 years with R/R B-cell ALL the overall 
remission rate within three months was 81%, the rates 
of event-free survival and OS were 73% (95% CI 60–82) 
and 90% (95% CI 81–95), respectively, at six months 
and 50% (95% CI 35–64) and 76% (95% CI 63–86) at 
12 months of follow-up [11]. 
Worth mentioning is the third, still ongoing, 
trial — TRANSCEND NHL-001 in R/R aggressive 
non-Hodgkin lymphomas (DLBCL, CLL, MZL, PMBCL, 
FL) with lisocabtagene maraleucel (liso-cel, Celgene). It 
reported an overall response rate (ORR) of 74%, and 
complete remission (CR) of 52% with only 1% and 15% 
of grade 3 or higher CRS and neuro toxicity, respectively, 
which seems to be highly promising compared with the 
data on Kymriah and Yercarta [13]. The other study of 
interest described the efficacy of CAR T-cells targeting 
B-cell maturation antigen (BCMA) expressed highly on 
multiple myeloma malignant cells. Twenty-one patents 
were reported to be treated with bb2121 (anti-BCMA 
CAR T-cells), with an ORR of 89% and follow-up ranging 
from 1.4 to 54.4 weeks, with only one progression among 
21 heavily pre-treated patients [14]. 
Availability
Although CAR T-cell therapy is undoubtedly highly 
effective, it is not available outside clinical trials and 
private health care system. The majority of clinical trials 
are carried on at facilities in China and in the USA, with 
the University of Pennsylvania being the leading one. 
In Europe, the only institutions having some experience 
with CAR T-cell clinical trials are in the Netherlands 
and in the UK [1, 15]. 
Due to cost concerns the UK’s NHS initially reject-
ed in August 2018 broad access to Gilead’s Yescarta, 
although the application sparked further discussion. 
Finally, late September 2018 brought an agreement 
that resulted in the founding by the NHS of a treatment 
programme with Yescarta for 200 adult patients with 
R/R large B-cell lymphoma a year and with Kymriah for 
30 R/R B-ALL children and young adults a year. This 
precedence makes the UK the first country in Europe 
offering, still to a limited number of patients, these novel 
and highly promising therapies.
Apart from clinical trials, several institutions offer 
private access to CAR T-cell therapy with costs fully 
covered by patients, with Israel and the USA being the 
leading ones. Yescarta and Kymriah cost $373,000 and 
$475,000, respectively. An NHS report last year, which 
summarised costs of treatment with Yescarta jointly with 
costs of conditioning therapy, hospitalisation, adverse 
event management, and follow-up, estimated the total 
cost at £583,362 compared with £80,106 for standard 
of care [16]. However, contrasting opinions seem to 
appear recently in peer-reviewed journals assessing 
life-years gained and quality-adjusted life-years (QA-
LYs) gained in favour of Kymriah vs. standard care. In 
cases of childhood R/R B-ALL, 40% of patients treated 
with Kymriah are expected to be long-term survivors 
with life-years gained of 10.34 years and 9.28 QALYs 
gained vs. 2.43 years and 2.10 QALYs gained for clo-
farabine treatment, in comparison. These enormous 
differences result in a cumulative cost-effectiveness 
ratio of $46,000 per QALY gained between Kymriah 
and clofarabine [17]. 
Potential in solid tumours
Translation of CAR T-cell success in haematology 
into the treatment of solid tumours is highly challenging 
due to many features of solid tumours that in haemato-
logical malignancies are minor obstacles. Using geneti-
cally modified lymphocytes to combat blasts that share 
haematopoietic origin and have the potential to migrate 
through the same locations, like blood, bone marrow, 
or lymph nodes, might contribute to anti-CD19 CAR 
T-cell therapy success. Due to genetic instability (so-
matic mutations) and heterogeneity, cancer cells have 
variable antigen expression levels on the surface of the 
cell between subclones of cancer cells. Additionally, 
antigens expressed by solid tumours are not exclusive 
comparing with healthy cells, being the foundation of 
serious “on-target off-tumour” side effects that limit 
its application [5]. Choosing an ideal tumour antigen 
(present on every malignant cell and not expressed on 
the surface of healthy ones) to be targeted by CAR 
T-cells seems to be the biggest obstacle. Many candidate 
antigens were under the scope, e.g. MUC1 [18, 19], 
HER2 [20], G2D [2], CEA [5], EGFR [5], GP100 [21], 
and mesothelin [2] among many others [22]. As an 
example, prostate-specific membrane antigen (PSMA) 
seems to be the perfect target, because preliminary data 
report it can be found on malignant prostate cells and 
the endothelium of some tumour vasculature, but it is 
not expressed by normal cells [2]. 
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The other obstacles are immunosuppressive proper-
ties of surrounding stroma that mute activation of the 
immune system. Sadly, T-cells do not infiltrate tumour 
tissue easily, and efforts are being made to implement 
additional receptors and co-stimulators into the CAR 
T-cell membrane to simplify its trafficking, as well as 
altering the chemokine secretion profile of the CAR 
T-cell to correlate with the cancer cells [2, 7]. Surpris-
ingly, the addition of anti-PD-1 antibody appeared to 
decrease the myeloid-derived suppressor cell (MDSC) 
population in the tumour stroma, and it augments the re-
sponse rate through increased CAR T-cell anti-tumour 
activity [5, 23]. 
Case series
Sadly, there are only a few case reports and trials 
on CAR T-cell in solid tumours. There are publications 
reporting CAR T-cell usage in patients diagnosed with 
malignant pleural mesothelioma [18], pancreatic ductal 
adenocarcinoma [18], colorectal adenocarcinoma [2, 
24], prostate cancer [2], breast cancer [25], melanoma 
[21], or osteosarcoma [20] among others. The majority 
of authors report poor outcomes of the treatment with 
rare and short-lasting ORR and occasional CR, mostly 
in melanoma cases [21]. A large number of clinical trials 
are still recruiting, and more data on clinical effective-
ness of CAR T-cell therapy in solid tumours are to be 
anticipated in near future. 
A ground-breaking case report of a female patient 
with chemorefractory metastatic breast cancer achieving 
CR after infusion of genetically modified T lymphocytes 
at the National Cancer Institute in Bethesda, USA was 
published in June 2018. Interestingly, researchers cre-
ated a suspension of four different T-cell clones directed 
against the four highest expressed antigens on the sur-
face of the patient’s cancer cells. After myeloablation 
therapy and infusion of modified autologous T-lympho-
cytes she continued pembrolizumab as a maintenance 
therapy and achieved CR after a year of treatment, and 
sustained it for 22 months of follow-up [25]. 
New ideas
Because CAR T-cell therapy, apart from its 
ground-breaking effectiveness, has some serious flaws, 
efforts are being made to alternate the original idea 
in order to overcome its limitations, e.g. serious and 
common side effects, robust manufacturing process, 
high costs. Studies are ongoing in both the public and 
private sector exploring different approaches to reach 
improvement. 
Using natural killer (NK) lymphocytes instead of 
T-lymphocytes for gene editing emerged as one of the 
major initiatives. The main advantage brought by the 
use of NK lymphocytes is that they ignite their activity 
regardless of human leukocyte antigen (HLA) match-
ing and for that reason do not need to be harvested 
from a patient or HLA-matched donor. This distinc-
tive feature makes CAR NK cell-based therapy an 
“off-the-shelf” resource for cancer therapy in contrast 
with CAR T-cells, which are highly personalised and 
produced specifically “for-the-patient”. 
The concept of creating CARs on the surface of 
NK-lymphocyte is not entirely new. NK-lymphocytes 
obtained from pooled peripheral or cord blood, as well 
as from cell line NK92, were previously genetically 
altered. In the case of NK92 cell line, to prevent perma-
nent engraftment of NK92 cells harvested initially from 
a non-Hodgkin lymphoma patient, altered lymphocytes 
needed to be additionally irradiated, but the procedure 
lowered significantly their viability and ability to prolife-
rate in vivo [26]. For all the aforementioned sources of 
NK-lymphocytes production process had comparable 
efficiency as in the case of T-lymphocytes, and, addition-
ally, infusions appeared to be much safer with rare side 
effects at much lower grades of intensity. Despite having 
lower toxicity, this therapy, surprisingly, turned out to 
be ineffective with negligible ORR rates [27]. 
However, a recent study published data on ge-
netically modified NK-lymphocytes obtained through 
transduction of genetic information on CARs into im-
munologically pluripotent stem cells (iPSC) that were 
afterwards forced to transform into NK lymphocytes 
expressing CAR. The process was described as extremely 
efficient with a high count of viable CAR NK-cells har-
vested. Ovarian cancer mice models were then infused 
with suspension of CAR NK-cells, among others, for 
comparison showing substantial and long-lasting regres-
sion of the tumour volume, proving its superiority above 
modified CAR T-cell therapy in this case [28].
CAR T cells are forced to express modified CAR 
particles among endogenous T-cell lymphocyte recep-
tors (TCR), receptors that are recognised as patient 
specific, and that is the main reason restricting it from 
being used in an “off-the-shelf” manner. Another 
example of an approach to overcome this obstacle is 
to genetically silence expression of native TCR on 
CAR T-cells that could be given regardless of HLA 
compatibility with no risk of triggering graft vs. host 
disease. Several companies made efforts in this area of 
research, as well as equipping CAR T-cells in suicide 
genes or other co-stimulatory particles that could add 
improvements if needed [2, 29]. Apart from large phar-
maceutical companies, biotechnology businesses like 
Cellectis, Parker Institute for Cancer Immunotherapy, 
or TMunity and others spread over the UK, Australia, 
China, or Singapore could be the best examples of at-
tempts to commercialise CAR T-cell therapies through 
the aforementioned improvements. 
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Conclusions
CAR T-cell therapy is considered highly innovative 
and effective, undoubtedly being the biggest break-
through in cancer treatment in years. However, clinical 
oncologists need to be aware not only of the obvious 
virtues of this approach but also its limitations. However, 
the race to create a cancer cure has not been won yet, 
and countless research teams are working on the idea 
of training lymphocytes to highly specifically, safel, 
and more efficiently deal with cancer cells, which will 
hopefully evolve into an “off-the-shelf” treatment with 
a more affordable price for caregivers. 
Regardless of further improvements, we should all 
be prepared for the implementation of therapy with 
genetically modified lymphocytes in the future. Most 
importantly, nowadays we also should be able to answer 
patients’ questions on this breakthrough treatment 
and inform them about its advantages and disadvan-
tages. Furthermore, we should all be aware of the pos-
sible side effects and its management, to be prepared 
for the moment when we can treat our patients with 
CAR T-cell therapies.
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